# This Study Will Investigate the Effect of Single Oral Doses of Retosiban on Cardiac Repolarization, With Moxifloxacin as a Positive Control in Healthy Volunteers.

> **NCT01702376** · PHASE1 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 52 (actual)

## Conditions studied

- Obstetric Labour, Premature

## Interventions

- **DRUG:** Retosiban 100 mg
- **DRUG:** Retosiban 800 mg
- **DRUG:** Placebo
- **DRUG:** Moxifloxacin 400 mg

## Key facts

- **NCT ID:** NCT01702376
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-10-03
- **Primary completion:** 2013-01-14
- **Final completion:** 2013-01-14
- **Target enrollment:** 52 (ACTUAL)
- **Last updated:** 2017-06-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01702376

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01702376, "This Study Will Investigate the Effect of Single Oral Doses of Retosiban on Cardiac Repolarization, With Moxifloxacin as a Positive Control in Healthy Volunteers.". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01702376. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*